Recursion Pharmaceuticals Valuation Multiples

Recursion Pharmaceuticals Overview

About Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Founded

2016

HQ

Employees

800

Website

recursion.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $77M

EBITDA: ($538M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Recursion Pharmaceuticals Financials

Recursion Pharmaceuticals reported last 12-month revenue of $77M and negative EBITDA of ($538M).

In the same LTM period, Recursion Pharmaceuticals generated $11M in gross profit, ($538M) in EBITDA losses, and had net loss of ($609M).

Recursion Pharmaceuticals P&L

In the most recent fiscal year, Recursion Pharmaceuticals reported revenue of $74M and EBITDA of ($559M).

Recursion Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals has current market cap of $2B, and enterprise value of $1B.

Recursion Pharmaceuticals' stock price is $3.63.

Recursion Pharmaceuticals Valuation Multiples

Recursion Pharmaceuticals trades at 17.1x EV/Revenue multiple, and (2.4x) EV/EBITDA.

Recursion Pharmaceuticals Financial Valuation Multiples

As of March 21, 2026, Recursion Pharmaceuticals has market cap of $2B and EV of $1B.

Equity research analysts estimate Recursion Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Recursion Pharmaceuticals has a P/E ratio of (3.1x).

Recursion Pharmaceuticals Margins & Growth Rates

Recursion Pharmaceuticals' revenue in the last 12 month grew by 27%.

Recursion Pharmaceuticals' revenue per employee in the last FY averaged $0.1M.

Recursion Pharmaceuticals' rule of 40 is (675%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Recursion Pharmaceuticals' rule of X is (634%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Recursion Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Recursion Pharmaceuticals M&A Activity

Recursion Pharmaceuticals acquired XXX companies to date.

Last acquisition by Recursion Pharmaceuticals was on XXXXXXXX, XXXXX. Recursion Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Recursion Pharmaceuticals Investment Activity

Recursion Pharmaceuticals invested in XXX companies to date.

Recursion Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Recursion Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).